A mutation in a single gene can cause endometrial cancer that is responsive to a specific drug therapy, researchers at UT Southwestern Medical Center have found in an animal study. The finding suggests that eventually it might be possible to screen women with endometrial cancer to see if they have that mutation and use the drug as targeted therapy, the researchers said…
Endometrial cancer is the most common cancer of the female reproductive tract, representing 6% of all cancers. There is currently no screening method or biomarker to indicate early presence of disease. “It is a very common malignancy that affects women of all ages” comments paper author Dr. Diego Castrillon…
As cancer survivors live longer, questions arise about what kind of care long-term survivors require. A recently published study from Case Western Reserve University’s Mandel School of Applied Social Sciences found 245 older married women who survived cancer had more health problems as compared to a sample of 245 married women without cancer…
Gail Entner Sonenshein, PhD, a professor in the department of biochemistry at Boston University School of Medicine, and director of the School’s Program in Research on Women’s Health, has been awarded the distinction of AAAS Fellow. Election as a Fellow is an honor bestowed upon AAAS members by their peers…
Ipsen (Paris:IPN) announced the initiation of an international, multi-center, controlled, randomized Phase II clinical trial to evaluate the safety and efficacy of BN83495, its investigational first-in-class steroid sulfatase (STS) inhibitor, in advanced endometrial cancer. BN83495 is currently being studied in several clinical studies in patients with hormone dependent cancers…
 |
We comply with the HONcode standard for trustworthy health information: verify here. |
 |
 |
